Abstract
Introduction/BackgroundPatient preference on treatment options following frontline platinum-based chemotherapy for epithelial ovarian cancer (EOC) remains unstudied. Multiple treatment options are available, including PARP inhibitors, so understanding patient preference is critical.MethodologyA cross-sectional survey was completed by US patients with newly-diagnosed EOC eligible for frontline maintenance therapy. Maintenance preference was assessed via time trade-off simulation. Patients selected their preferred post-chemotherapy treatment approach: surveillance, oral daily (QD), oral twice daily (BID), intravenous every 3 weeks (IV-Q3W), or combination IV-Q3W/BID, assuming equivalent efficacy (for all scenarios) and safety (medication scenarios only). Patients were asked to select between a series of maintenance scenarios comparing decreased time to progression (TTP) on their preferred option with constant TTP with alternative options. Relative disutility of each scenario was calculated.Abstract 2022-RA-949-ESGO Table 1Patient (N=153) preferences for formulation and dosing frequency of frontline maintenance for EOCResults153 patients completed the survey, median age was 52.3 years; 30% were non-White, and 83% had health insurance covering full EOC treatment. Of all medication strategies, QD treatment was preferred (38%, table 1); patients were willing to trade the least amount of time (2.3 months) without progression on this scenario versus other choices. For patients who preferred to take a medication even when surveillance offered the same amount of time without progression (n=86), the most common reason was a feeling of taking an active approach to treatment (66%), having a reason to regularly visit a doctor/hospital (30%), being cared for/monitored more regularly and carefully (28%), and because taking medication is reassuring (24%).ConclusionPatients preferred QD treatment more than other medication strategies for EOC maintenance following frontline platinum-based chemotherapy; patients who preferred medication felt they were taking an active approach to treatment. Patient preferences should be considered in treatment decisions and further studied.Previously submitted to the IGCS Global Meeting (29 Sept–1 Oct 2022; New York City, USA)Funding statementGSK (214511/NCT02655016).